The results show that the efficacy of vemurafenib and trametinib in CRC cells depends on the presence of mutant BRAF (V600E) and an efficient inhibition of MEK/ERK signaling, whereas regorafenib action was largely independent of the molecular status of the cells and perifosine showed a cell line-specific action profile. This evidence concerns the gene BRAF and colorectal carcinoma.